Detection of hematogenous micrometastasis in patients with transitional cell carcinoma

被引:39
|
作者
Güdemann, CJ
Weitz, J
Kienle, P
Lacroix, J
Wiesel, MJ
Soder, M
Benner, A
Staehler, G
Doeberitz, MV
机构
[1] Univ Heidelberg, Chirurg Klin, Sekt Mol Diagnost & Therapie, Div Mol Diagnost & Therapy,Dept Urol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Dept Surg, D-6900 Heidelberg, Germany
[3] German Canc Res Ctr, Cent Unit Biostat, D-6900 Heidelberg, Germany
关键词
circulating tumor cells; reverse transcriptase; polymerase chain reaction; transitional cell carcinoma; metastasis;
D O I
10.1016/S0022-5347(05)67418-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Cytokeratin 20 (CK 20) is selectively expressed in urothelium, gastric intestinal epithelium, in Merkel cells and in a variety of malignant neoplasms. CK 20 RT-PCR assay has been extensively used to detect isolated cancer cells in peripheral blood, lymph nodes and bone marrow samples of patients with colorectal carcinoma. Since CK-20 is also actively expressed in transitional cell carcinoma (TCC), we analyzed, whether CK 20 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is suitable to detect residual tumor cells in patients with transitional cell carcinoma of the bladder and the upper urinary tract. Materials and Methods: Nested Reverse Transcriptase Polymerase Chain Reaction assay was used to analyze CK 20 transcripts in peripheral venous blood samples and tumor biopsies of 49 patients with transitional cell carcinoma. Blood samples of 22 healthy volunteers served as negative controls. Results: CK 20 mRNA was detectable in blood samples of 12 of 49 patients with TCC. All blood samples of the control group tested negative. The detection rate for CK 20 mRNA significantly correlated (p = 0.0019, Cochran-Armitage Trend Test;) to the stage of disease and increased from 0% in stage pTa to 63% in stage pT4. Conclusions: These results suggest that CK 20 is a suitable marker for the detection of disseminated TCC cells in peripheral venous blood samples and may be helpful in the molecular staging of TCC patients. The prognostic relevance has to be evaluated in further followup,
引用
收藏
页码:532 / 536
页数:5
相关论文
共 50 条
  • [1] Hematogenous dissemination of transitional cell carcinoma in the bladder to the prostate
    Liedberg, F
    Chebil, G
    Månsson, W
    SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2003, 37 (04): : 36 - 360
  • [2] Transitional cell carcinoma in dialysis patients
    Ou, JH
    Pan, CC
    Lin, JSN
    Tzai, TS
    Yang, WH
    Chang, CC
    Cheng, HL
    Lin, YM
    Tong, YC
    EUROPEAN UROLOGY, 2000, 37 (01) : 90 - 94
  • [3] Transitional cell carcinoma of the ovary
    Ichigo, Satoshi
    Takagi, Hiroshi
    Matsunami, Kazutoshi
    Murase, Takayuki
    Ikeda, Tsuneko
    Imai, Atsushi
    ONCOLOGY LETTERS, 2012, 3 (01) : 3 - 6
  • [4] Immunohistochemical detection of cyclin E in transitional cell carcinoma
    Bogdanovic, Lj.
    Radojevic-Skodric, S.
    Lazic, M.
    Bogdanovic, J.
    Spasic, D.
    Milenkovic, S.
    Puskas, L.
    Basta-Jovanovic, G.
    JOURNAL OF BUON, 2011, 16 (04): : 727 - 732
  • [5] Detection of circulating uroplakin-positive cells in patients with transitional cell carcinoma of the bladder
    Li, SM
    Zhang, ZT
    Chan, S
    McLenan, O
    Dixon, C
    Taneja, S
    Lepor, H
    Sun, TT
    Wu, XR
    JOURNAL OF UROLOGY, 1999, 162 (03) : 931 - 935
  • [6] Micrometastasis: Detection methods and clinical importance
    Balic, Marija
    Williams, Anthony
    Dandachi, Nadia
    Cote, Richard J.
    CANCER BIOMARKERS, 2011, 9 (1-6) : 397 - 419
  • [7] Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation
    Lininger, RA
    Ashfaq, R
    AlboresSaavedra, J
    Tavassoli, FA
    CANCER, 1997, 79 (10) : 1933 - 1943
  • [8] Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma
    Volkmer, BG
    Seidl-Schlick, EM
    Bach, D
    Romics, I
    Kleinschmidt, K
    CLINICAL RHEUMATOLOGY, 2005, 24 (04) : 319 - 323
  • [9] Cyclophosphamide is contraindicated in patients with a history of transitional cell carcinoma
    Bjoern G. Volkmer
    Evelyn M. Seidl-Schlick
    Dietmar Bach
    Imre Romics
    Klaus Kleinschmidt
    Clinical Rheumatology, 2005, 24 : 319 - 323
  • [10] A kidney carcinoma with features of clear cell renal carcinoma and transitional cell carcinoma: a combined renal cell and transitional cell carcinoma?
    Terada, T
    Inatsuchi, H
    Yasuda, M
    Osamura, Y
    VIRCHOWS ARCHIV, 2003, 443 (04) : 583 - 585